<DOC>
	<DOCNO>NCT01843946</DOCNO>
	<brief_summary>Roxithromycin effective treatment intracellular organism , include chlamydia mycoplasma , exhibit anti-inflammatory immunomodulatory effect respiratory disease . To explore potential therapeutic benefit roxithromycin chronic prostatitis/chronic pelvic pain syndrome ( CP/CPPS ) , study compare effect roxithromycin ciprofloxacin aceclofenac .</brief_summary>
	<brief_title>Clinical Efficacy Roxithromycin Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome</brief_title>
	<detailed_description>A total 75 patient CP/CPPS randomize three group open-label : group 1 , ciprofloxacin ; group 2 , aceclofenac ; group 3 , roxithromycin . The patient treat 4 week subsequently follow 12 week . Changes baseline total domain score NIH Chronic Prostatitis Symptom Index ( NIH-CPSI ) evaluate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Diagnosis category IIIa IIIb chronic prostatitis NIHCPSI ( National Institute Health Chronic Prostatitis Symptom Index ) score â‰¥ 15 Urinary tract infection uropathogen within past 12 month Serious medical problem NIH consensus exclusion criteria13 ( presence active urethritis , urogenital cancer , urinary tract disease , functionally significant urethral stricture , neurological disease affect bladder , etc . ) Drug therapy might affect low urinary tract function within past 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>